Esperion Therapeutics (NASDAQ:ESPR) 公佈其季度每股虧損$(0.11)，較分析師的共識預期$(0.16)高出31.25%。與去年同期每股虧損$(0.50)相比，這實現了78%的改善。公司季度銷售額爲$69.11M，超出分析師共識預期$61.58M，高出12.22%。與去年同期的銷售額$32.25M相比，這增長了114.30%。

以上內容來自Benzinga Earnings專欄，原文如下：

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by 31.25 percent. This is a 78 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $69.11 million which beat the analyst consensus estimate of $61.58 million by 12.22 percent. This is a 114.30 percent increase over sales of $32.25 million the same period last year.